fc188 live
2025-01-09

Adele bids tearful farewell to her Las Vegas residency: I will miss it terriblySince then, business titans, political giants and global film stars have all been among those ringing the opening bell at the NYSE. Ronald Reagan rang the bell as president in 1985. Billionaire businessman and former New York City Mayor Michael Bloomberg and Hollywood star Robert Downey Jr. have also rung the bell. The list even includes famous Muppets: Miss Piggy was once a bell ringer. President-elect Donald Trump joined that list Thursday when he opened trading at the famous stock exchange on Wall Street. He was accompanied by his wife, Melania, who interestingly enough received the honor before her husband. As first lady, she rang the bell in 2019 as part of her “Be Best” program. Bell-ringers are more commonly founders and executives chosen primarily from the exchange's more than 2,300 listed companies. Over the last few months, the guests have included executives from Alaska Air Group, Bath & Body Works, and Ally Financial. Stock trading around the location of the NYSE's current home has deep roots that trace back to the Dutch founding of New Amsterdam and when Wall Street had an actual wall. The NYSE traces its direct roots to the “Buttonwood Agreement” signed in 1792, which set rules for stock trading and commissions. The NYSE moved into its first permanent home in 1865. The first bell in use was actually a gong. The exchange moved into its current iconic building in 1903 and started using an electronically operated brass bell. That has evolved into synchronized bells in each of the NYSE’s four trading areas.
Georgia QB Carson Beck declares for 2025 NFL Draft
IRVINE, Calif. , Dec. 19, 2024 /PRNewswire/ -- OrthAlign, Inc. today announced a significant milestone with the successful first clinical use of its Lantern Hip handheld technology. The procedure was performed by Edwin Su, MD, a renowned orthopedic surgeon at the Hospital for Special Surgery (HSS) in New York, NY . "The first clinical case of Lantern Hip is a monumental achievement for our team and the surgeons involved with this project," said Eric Timko , CEO of OrthAlign. "This expansion of our flagship platform to include hips not only enhances our product portfolio, but also positions us for significant growth in both the hospital and the ambulatory surgery center (ASC). We're excited to kick off the new year with Lantern Hip and showcase its impact at the American Academy of Orthopaedic Surgeons annual meeting," says Eric Timko . Lantern Hip is the latest evolution in hip technology, built upon the success of over 375,000 OrthAlign procedures worldwide. Next-generation sensors, powered by accelerometers and gyroscopes, are designed to provide an accurate and simple solution to navigate cup placement and measure changes in leg length and offset. The system enables the surgeon to choose their preferred implant, and is accessible to any site of service. "Lantern Hip allows me to personalize cup position for each patient," said Dr. Su. "I can compare the functional pelvic plane (FPP), the anterior pelvic plane (APP), and the coronal plane during live cup navigation, so I can place the implant in the best position for function and stability. With its triple-sensor technology, Lantern Hip also allows me to feel confident in my leg length and offset restoration. The system was simple for me and my team to integrate into our workflow during our first case, and I expect this will make a positive impact on other surgeons' experience too." OrthAlign will continue to offer surgeons the opportunity to experience Lantern Hip firsthand through webinars and demonstrations at industry events throughout 2025. For inquiries about upcoming events or to schedule a product demonstration, contact your local OrthAlign representative. Visit www.orthalign.com/lanternhip to view the Lantern Hip introductory video. Lantern Hip is indicated for use in direct anterior total hip arthroplasty procedures with the patient in the supine position. About OrthAlign, Inc. OrthAlign is a medical device company with a focus on delivering practical, cutting-edge technologies for orthopedic surgery. With a commitment to innovation and excellence, OrthAlign provides surgeons with user-friendly, cost-effective solutions to help improve patient care in joint replacement. In 2023, the company celebrated a record-breaking year with over $50 million in global revenue, reflecting its dedication to growth and leadership in the industry. Driven by the belief that everyone deserves exceptional healthcare, OrthAlign is committed to making empowering technologies accessible to all. LANTERN ® and ORTHALIGN ® are registered trademarks of OrthAlign, Inc. View original content to download multimedia: https://www.prnewswire.com/news-releases/orthalign-inc-announces-first-cases-using-lantern-hip-the-next-evolution-in-total-hip-replacement-technology-302336610.html SOURCE OrthAlignJoey Logano calls out critics of NASCAR Cup Series championship win
IRVINE, Calif. , Dec. 19, 2024 /PRNewswire/ -- OrthAlign, Inc. today announced a significant milestone with the successful first clinical use of its Lantern Hip handheld technology. The procedure was performed by Edwin Su, MD, a renowned orthopedic surgeon at the Hospital for Special Surgery (HSS) in New York, NY . "The first clinical case of Lantern Hip is a monumental achievement for our team and the surgeons involved with this project," said Eric Timko , CEO of OrthAlign. "This expansion of our flagship platform to include hips not only enhances our product portfolio, but also positions us for significant growth in both the hospital and the ambulatory surgery center (ASC). We're excited to kick off the new year with Lantern Hip and showcase its impact at the American Academy of Orthopaedic Surgeons annual meeting," says Eric Timko . Lantern Hip is the latest evolution in hip technology, built upon the success of over 375,000 OrthAlign procedures worldwide. Next-generation sensors, powered by accelerometers and gyroscopes, are designed to provide an accurate and simple solution to navigate cup placement and measure changes in leg length and offset. The system enables the surgeon to choose their preferred implant, and is accessible to any site of service. "Lantern Hip allows me to personalize cup position for each patient," said Dr. Su. "I can compare the functional pelvic plane (FPP), the anterior pelvic plane (APP), and the coronal plane during live cup navigation, so I can place the implant in the best position for function and stability. With its triple-sensor technology, Lantern Hip also allows me to feel confident in my leg length and offset restoration. The system was simple for me and my team to integrate into our workflow during our first case, and I expect this will make a positive impact on other surgeons' experience too." OrthAlign will continue to offer surgeons the opportunity to experience Lantern Hip firsthand through webinars and demonstrations at industry events throughout 2025. For inquiries about upcoming events or to schedule a product demonstration, contact your local OrthAlign representative. Visit www.orthalign.com/lanternhip to view the Lantern Hip introductory video. Lantern Hip is indicated for use in direct anterior total hip arthroplasty procedures with the patient in the supine position. About OrthAlign, Inc. OrthAlign is a medical device company with a focus on delivering practical, cutting-edge technologies for orthopedic surgery. With a commitment to innovation and excellence, OrthAlign provides surgeons with user-friendly, cost-effective solutions to help improve patient care in joint replacement. In 2023, the company celebrated a record-breaking year with over $50 million in global revenue, reflecting its dedication to growth and leadership in the industry. Driven by the belief that everyone deserves exceptional healthcare, OrthAlign is committed to making empowering technologies accessible to all. LANTERN ® and ORTHALIGN ® are registered trademarks of OrthAlign, Inc. SOURCE OrthAlignGeneva, Switzerland, Dec. 19, 2024 (GLOBE NEWSWIRE) -- SEALSQ Corp (NASDAQ: LAES) ("SEALSQ" or "Company"), a company that focuses on developing and selling Semiconductors, PKI and Post-Quantum technology hardware and software products, today announced that it has completed a registered direct offer to several institutional investors of 13,157,896 ordinary shares at a public offering price of $1.90, for gross proceeds of $25.0 million (the “Offering”), before deducting commissions and offering expenses. This brings the total gross proceeds from financings completed this week to $60.0 million, before deducting commissions and offering expenses. The Company confirms that, given the terms of the financings completed in the last week, it does not currently expect to enter into any further registered direct offering of ordinary shares for at least the next 60 days as a result of the funds raised. Maxim Group LLC acted as the sole placement agent for the Offering. SEALSQ currently intends to utilize the net proceeds from the Offering to fund the deployment of its next-generation post-quantum semiconductor technology and ASIC capabilities in the United States, to support working capital and for general corporate purposes. Carlos Moreira, CEO of the SEALSQ, said, “We are delighted to have secured this financing, which enables us to focus on advancing our quantum strategy, particularly the development and market launch of our post-quantum chips. The funds raised over the past week will significantly support the achievement of our strategic goals. As we move into the new year, we look forward to sharing further details on the Company's next steps.” The securities described above were offered by the Company pursuant to an effective shelf registration statement on Form F-3 (File No. 333-283358) previously filed with and subsequently declared effective by the U.S. Securities and Exchange Commission (“SEC”) on November 27, 2024. A prospectus supplement relating to the securities issued in, and describing the terms of, the Offering was filed by the Company with the SEC. Copies of the prospectus supplement relating to the Offering, together with the accompanying prospectus, can be obtained at the SEC's website at www.sec.gov or by contacting Maxim Group LLC, at 300 Park Avenue, 16th Floor, New York, NY 10022, Attention: Syndicate Department, or via email at syndicate@maximgrp.com or by telephone at (212) 895-3745. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About SEALSQ: SEALSQ focuses on selling integrated solutions based on Semiconductors, PKI and Provisioning services, while developing Post-Quantum technology hardware and software products. Our solutions can be used in a variety of applications, from Multi-Factor Authentication tokens, Smart Energy, Smart Home Appliances, Medical and Healthcare and IT Network Infrastructure, to Automotive, Industrial Automation and Control Systems. Post-Quantum Cryptography (PQC) refers to cryptographic methods that are secure against an attack by a quantum computer. As quantum computers become more powerful, they may be able to break many of the cryptographic methods that are currently used to protect sensitive information, such as RSA and Elliptic Curve Cryptography (ECC). PQC aims to develop new cryptographic methods that are secure against quantum attacks. For more information, please visit www.sealsq.com. Forward Looking Statements This communication expressly or implicitly contains certain forward-looking statements concerning SEALSQ Corp and its businesses. Forward-looking statements include statements regarding our business strategy, financial performance, results of operations, market data, events or developments that we expect or anticipates will occur in the future, as well as any other statements which are not historical facts. Although we believe that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates which are inherently subject to significant uncertainties and contingencies, many of which are beyond our control. Actual results may differ materially from those expressed or implied by such forward-looking statements. Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include SEALSQ’s ability to implement its growth strategies; SEALSQ’s ability to successfully launch post-quantum semiconductor technology; SEALSQ’s ability to capture a share of the quantum semiconductor market; the growth of the quantum computing market; SEALSQ’s ability to expand its U.S. operations; SEALSQ’s ability to make additional investments towards the development of a new generation of quantum-ready semiconductors; SEALSQ’s ability to continue beneficial transactions with material parties, including a limited number of significant customers; market demand and semiconductor industry conditions; the growth of the quantum computing market; and the risks discussed in SEALSQ’s filings with the SEC. Risks and uncertainties are further described in reports filed by SEALSQ with the SEC. SEALSQ Corp is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. Press and Investor Contacts SEALSQ Corp. Carlos Moreira Chairman & CEO Tel: +41 22 594 3000 info@sealsq.com SEALSQ Investor Relations (US) The Equity Group Inc. Lena Cati Tel: +1 212 836-9611 / lcati@equityny.com Katie Murphy Tel: +212 836-9612 / kmurphy@equityny.com
AUM of USD 635 Billion at ADFW Caps Stellar Q4 as Trillion-Dollar Club Flock to ADGMNone
Related hot word search:
Previous: fc188 link
Next: fc188 logo